Prophase labs announces update on pharmaloz manufacturing, inc. progress

Pmi revenues and earnings projected to grow significantly in the second half of 2024 and full year 2025. new strategic initiatives for pmi create significant opportunities for liquidity and value creation garden city, ny, july 11, 2024 (globe newswire) -- prophase labs, inc. (nasdaq: prph) (“prophase” or the “company”), a next-generation biotech, genomics, and diagnostics company, today reported that pharmaloz manufacturing, inc. (“pmi”), its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025.
PRPH Ratings Summary
PRPH Quant Ranking